Options Traders Pick Up Pharma Stock After Eli Lilly Buyout
Why it matters: Eli Lilly's $7.8 billion acquisition of Centessa Pharma and new drug approval will reshape the pharmaceutical landscape.
- Options traders are actively picking up pharma stocks, signaling heightened interest in the sector.
- Eli Lilly is acquiring Centessa Pharma for a substantial sum of up to $7.8 billion, causing Centessa shares to skyrocket.
- Eli Lilly also secured US approval for its new weight-loss pill, expanding its market presence.
- Apellis Pharma shares surged due to a deal with Biogen, leading to discussions on whether it's too late for investors to pursue APLS stock.
- Yahoo Finance highlights the significant stock movements for both Centessa and Apellis, underscoring the impact of these deals.
Options traders are showing increased interest in pharma stocks following Eli Lilly's significant acquisition of Centessa Pharma for up to $7.8 billion, which caused Centessa shares to skyrocket. This comes as Eli Lilly also secured US approval for its weight-loss pill, while Apellis Pharma saw its stock surge due to a separate deal with Biogen, prompting questions about whether it's too late for investors to chase APLS stock.
